This is a ready-to-use viral clearance study protocol for a biologics purification step. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal document control, review, and approval before execution begins. A worked filled specimen follows the template. Verify each cited regulation against the current source before you rely on it. This is general guidance to adapt, not legal or regulatory advice; live-virus work is typically executed at a specialized contract virology laboratory under its own biosafety controls.
Approval page (execute only after all signatures)
| Field | Entry |
|---|---|
| Protocol title | Viral Clearance Study for <<FILL: PROCESS STEP, e.g. Protein A capture / low-pH inactivation / AEX / viral filtration>> |
| Protocol number | <<FILL: PROT-ID, e.g. VAL-VC-011>> |
| Version | <<FILL: version, e.g. 1.0>> |
| Effective date | <<FILL: date>> |
| Supersedes | <<FILL: prior version or "New">> |
| Product / process | <<FILL: product name, process stage>> |
| Testing site | <<FILL: contract virology laboratory name and location>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Process development / Validation) | <<FILL>> | ||
| Virology lab study director | <<FILL>> | ||
| Analytical / assay lead | <<FILL>> | ||
| Quality Assurance (approver) | <<FILL>> |
1. Objective
To demonstrate the capability of <<FILL: PROCESS STEP(S)>> to remove or inactivate a defined panel of model viruses, expressed as log reduction values (LRV), and to establish that the cumulative process clearance provides an adequate safety margin against the estimated viral burden of the unprocessed bulk, per ICH Q5A(R2).
2. Scope
In scope: the process step(s) <<FILL: list, e.g. low-pH viral inactivation; AEX flow-through; 20 nm viral filtration>> for <<FILL: PRODUCT>>, at the scale-down model described in section 5. Out of scope: cell-substrate characterization and raw-material screening, which are addressed under the parallel controls of the viral safety program (adventitious agent testing, cell bank characterization) and are not repeated here.
3. Model virus panel and rationale
| Virus | Family | Genome / envelope | Role in panel | Rationale |
|---|---|---|---|---|
<<FILL: e.g. X-MuLV>> | <<FILL: retrovirus>> | <<FILL: RNA, enveloped>> | <<FILL: relevant virus for the cell substrate>> | <<FILL: mandatory for rodent cell lines>> |
<<FILL: e.g. MVM/MMV>> | <<FILL: parvovirus>> | <<FILL: DNA, non-enveloped>> | <<FILL: worst-case small non-enveloped challenge>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
<<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
State why this panel spans envelope status, genome type, and particle size: <<FILL: rationale>>.
4. Worst-case process conditions challenged
State the least-favorable condition within the validated operating range for each parameter, not the nominal condition.
| Parameter | Nominal | Worst case challenged | Rationale |
|---|---|---|---|
<<FILL: e.g. inactivation pH>> | <<FILL: e.g. 3.5>> | <<FILL: e.g. 3.7, high end, least inactivation>> | <<FILL>> |
<<FILL: hold time>> | <<FILL>> | <<FILL: shortest validated hold>> | <<FILL>> |
<<FILL: resin/membrane age>> | <<FILL>> | <<FILL: end-of-life, oldest validated cycle count>> | <<FILL>> |
<<FILL: load challenge>> | <<FILL>> | <<FILL: highest validated load>> | <<FILL>> |
<<FILL: linear velocity / flux>> | <<FILL>> | <<FILL>> | <<FILL>> |
5. Scale-down model qualification (prerequisite, must be complete before execution)
| Attribute | Manufacturing scale | Scale-down model | Equivalent? |
|---|---|---|---|
| Bed height / membrane area | <<FILL>> | <<FILL>> | <<FILL: Yes/No + basis>> |
| Linear velocity / flux | <<FILL>> | <<FILL>> | <<FILL>> |
| Load ratio (g product / L resin, or L/m2) | <<FILL>> | <<FILL>> | <<FILL>> |
| Buffer composition, pH, conductivity | <<FILL>> | <<FILL>> | <<FILL>> |
| Resin lot / membrane lot | <<FILL>> | <<FILL: same lot or qualified equivalent>> | <<FILL>> |
Scale-down model qualification report reference: <<FILL: report number>>. Do not begin spiking without this qualification approved.
6. Responsibilities
| Role | Responsibility |
|---|---|
| Process development / Validation lead | Designs the protocol, defines worst-case conditions, interprets results into the process clearance claim |
| Virology lab study director | Executes spiking, holds BSL-appropriate containment, performs infectivity assays, issues the raw data report |
| Analytical / assay lead | Qualifies the infectivity/interference assay for the product matrix, including cytotoxicity check |
| Quality Assurance | Approves protocol and report, confirms GLP/GMP-appropriate documentation, reviews contract lab data package for data integrity |
| Regulatory affairs | Uses the LRV package to compile the viral safety section of the dossier |
7. Assay qualification and interference/cytotoxicity check
Before spiking, confirm the chosen infectivity assay (e.g., TCID50 or plaque assay) detects the model virus in the product matrix without the product buffer masking or killing the indicator cells. Record: <<FILL: cytotoxicity result>>, <<FILL: interference result>>, <<FILL: assay limit of detection>>. A supporting orthogonal measure (e.g., qPCR) may be run in parallel: <<FILL: yes/no, method>>.
8. Test cases
| TC ID | Step | Virus | Spike titer (log10) | Load volume | Sample point | Expected | Actual | LRV | Pass/Fail |
|---|---|---|---|---|---|---|---|---|---|
| TC-01 | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | Pre-step (load) | Titer determined | <<FILL>> | ||
| TC-02 | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> | Post-step (product pool) | Titer determined | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-03 (inactivation kinetics) | <<FILL>> | <<FILL>> | <<FILL>> | n/a | Time points: <<FILL: e.g. 0, 15, 30, 60 min>> | Kill curve to below detection | <<FILL>> | <<FILL>> | <<FILL>> |
Total virus (titer x volume), not titer alone, is what carries into the LRV calculation; use the paired Worksheet: LRV and Viral Clearance Summary Calculation to compute and document each value.
9. Acceptance criteria
- Each studied step yields a defined or bounded LRV (a below-detection result is reported as a ”>” value bounded by assay sensitivity and spike volume, never as an absolute number).
- Cumulative process LRV, summed only across mechanistically orthogonal steps, exceeds the estimated viral burden of the unprocessed bulk by a documented safety margin, per ICH Q5A(R2).
- The relevant virus for the cell substrate (e.g., an endogenous retrovirus for a rodent line) is cleared with a large, documented safety factor.
- Inactivation steps present a kinetic (time-course) profile showing the kill is essentially complete before the process hold time, not a single endpoint.
- Assay cytotoxicity/interference is ruled out or corrected for.
10. Deviation handling
Any deviation from the protocol (a missed sample, an out-of-range process parameter during execution, an assay anomaly) is raised and investigated through <<FILL: SOP-ID for deviations>>, and its impact on the LRV claim is assessed and documented before the study is considered complete.
11. Summary and conclusion (completed at report stage)
Reference the viral clearance study report <<FILL: report number>>, which states the LRV per step, the cumulative clearance per virus, the safety margin calculation, all deviations and their impact, and the conclusion.
12. References
ICH Q5A(R2), Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin (2023 revision). ICH Q5E, Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process. FDA Guidance for Industry, Process Validation: General Principles and Practices (January 2011). EMA Guideline on process validation for the manufacture of biotechnology-derived active substances (2016). EudraLex Volume 4, Annex 2 (biological substances) and Annex 15 (qualification and validation).
Confirm the current version and clause numbers of each reference before issue.
13. Attachments
Scale-down model qualification report; assay qualification/cytotoxicity report; contract lab raw data package; resin/membrane age and cycle-count records for the challenge material.
14. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen (excerpt)
Illustrative example for a Protein A capture and low-pH inactivation step against X-MuLV. Numbers are illustrative; replace with your own study data.
Worst-case conditions challenged:
| Parameter | Nominal | Worst case challenged | Rationale |
|---|---|---|---|
| Inactivation pH | 3.5 | 3.7 (high end of range) | Least inactivation within validated range |
| Hold time | 90 min | 60 min (shortest validated hold) | Least contact time |
| Resin age | Fresh to 150 cycles | 150 cycles (end of validated life) | Aged resin has lower binding capacity |
Test case result:
| TC ID | Step | Virus | Sample point | LRV | Pass/Fail |
|---|---|---|---|---|---|
| TC-02 | Low-pH inactivation | X-MuLV | Post-step, 60 min hold, pH 3.7, 150-cycle resin | greater than 5.3 (below detection) | Pass |
Cumulative clearance conclusion (illustrative): low-pH inactivation (greater than 5.3) plus AEX flow-through (greater than 4.5) plus viral filtration (greater than 4.2) gives a cumulative process LRV for X-MuLV of greater than 14.0, which exceeds the estimated retrovirus-like particle burden in the unprocessed bulk by a wide margin, consistent with ICH Q5A(R2) expectations for a relevant virus in a rodent cell line.
Common inspection findings this protocol prevents
- LRV claimed from a scale-down model with no documented equivalence to manufacturing scale.
- Clearance studied at nominal, not worst-case, process conditions.
- Clearance claimed on fresh resin only, with no end-of-life challenge.
- LRVs from two non-orthogonal steps summed without justification.
- A below-detection result reported as an absolute LRV rather than a bounded “greater than” value.
- Single-endpoint inactivation data with no kinetic time course.
How to adapt this protocol
- Set your protocol number, product, and testing site in the approval page.
- Build the virus panel from your cell substrate and process type; confirm the mandatory “relevant virus” for your line.
- Pull worst-case parameter values from your validated operating ranges, not nominal setpoints.
- Attach your scale-down model qualification before execution; do not run spiking against an unqualified model.
- Use the paired LRV worksheet to compute and document every value consistently.
- Confirm every regulation in section 12 against the current published version before issue.